摘要
研究背景和目标:抑制热休克蛋白HSP90是治疗胰腺癌(PC)的潜在战略,因为许多HSP90客户蛋白在PC中过表达或发生突变。而这些客户蛋白直接参与调节PC的扩增和加剧。我们前期的研究发现Y306zh是潜在的新颖的HSP90抑制剂,这项研究中我们更进一步探索Y306zh作为抗PC药物的作用机制。 材料和方法:通过荧光偏振法分析Y306zh对HSP90的结合亲和力。使用人类PC细胞株和Miapaca2胰腺癌异种移植模型研究Y306zh的抗增殖活性和分子机制。 结果:Y306zh与HSP90的氨基末端结合紧密,IC50为85 nM,这导致了ATP不能再与相同位点结合,并影响HSP90-p23复合体形成。Y306zh也能诱导HSP70的表达,聚集形成CHIP、 HSP70和 HSP90复合体,并通过蛋白酶体途径最终导致HSP90客户蛋白(EGFR, AKT, C-RAF and CDK4)的降解。令人惊讶的是,与分子机理一致,Y306zh通过对细胞G2/M期阻滞抑制PC细胞增殖,但对正常的哺乳动物细胞完全不敏感。而且Y306zh有效抑制Miapaca2胰腺癌异种移植小鼠的肿瘤生长而不明显影响小鼠体重。 结论:Y306zh,是一种新型的HSP90抑制剂,能中断ATP结合至HSP90从而扰乱HSP90-p23的相互作用,并最终抑制胰腺癌细胞的生长。
关键词: 分子伴侣复合体,客户蛋白,热休克蛋白90,胰腺癌,p23
图形摘要
Current Cancer Drug Targets
Title:Antiproliferative Effect of HSP90 Inhibitor Y306zh Against Pancreatic Cancer is Mediated by Interruption of AKT and MAPK Signaling Pathways
Volume: 14 Issue: 7
Author(s): Nina Xue, Jing Jin, Di Liu, Rui Yan, Sen Zhang, Xiaoming Yu and Xiaoguang Chen
Affiliation:
关键词: 分子伴侣复合体,客户蛋白,热休克蛋白90,胰腺癌,p23
摘要: Background and Aim: Inhibition of HSP90 is a potential strategy to treat pancreatic cancer (PC), since many client proteins of HSP90 are found to be over-expressed and/or genetically mutated in PC. These client proteins directly participate in the modulation of proliferation and aggravation of PC. Our previous works led to Y306zh as a novel and potent HSP90 inhibitor. In this study we further investigated the mode of actions of Y306zh as an anti-PC agent.
Materials and Methods: The binding affinity of Y306zh towards HSP90 was analyzed by fluorescence polarization assay. The anti-proliferative activities and molecular mechanism of Y306zh were investigated in human PC cell lines and Miapaca2 xenograft model.
Results: Y306zh binds tightly to the NH2-terminus of HSP90 with an IC50 of 85 nM, and this causes ATP incapable to attach to the same binding site, and disrupts HSP90-p23 association. Y306zh also induces the expression of HSP70, recruits the complex of CHIP, HSP70 and HSP90, and eventually results in the degradation of HSP90 client proteins (EGFR, AKT, C-RAF and CDK4) via proteasomal pathway. Amazingly, coincident with the molecular mechanism, Y306zh also inhibits the proliferation of PC cells through G2/M phase arrest, but appears to be totally insensitive to normal mammalian cells. Furthermore, Y306zh effectively inhibits tumor growth of Mia-paca2 xenograft mice without any obvious effect on body weight.
Conclusions: Y306zh, a novel HSP90 inhibitor, interrupts ATP binding to HSP90 and disrupts HSP90-p23 interaction, and eventually inhibits the growth of PC cells.
Export Options
About this article
Cite this article as:
Xue Nina, Jin Jing, Liu Di, Yan Rui, Zhang Sen, Yu Xiaoming and Chen Xiaoguang, Antiproliferative Effect of HSP90 Inhibitor Y306zh Against Pancreatic Cancer is Mediated by Interruption of AKT and MAPK Signaling Pathways, Current Cancer Drug Targets 2014; 14 (7) . https://dx.doi.org/10.2174/1568009614666140908101523
DOI https://dx.doi.org/10.2174/1568009614666140908101523 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Five-gene Signature for Predicting the Prognosis of Colorectal Cancer
Current Gene Therapy Insights in Nanoparticle-Bacterium Interactions: New Frontiers to Bypass Bacterial Resistance to Antibiotics
Current Pharmaceutical Design Current Status and Future of Target-Based Therapeutics
Current Cancer Drug Targets Synthesis and Evaluation of A New Series of Thiazole Derivatives as Potential Antitumor Agents and MMP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Pyrazolo-Triazolo-Pyrimidine Derivatives as Adenosine Receptor Antagonists: A Possible Template for Adenosine Receptor Subtypes?
Current Pharmaceutical Design Epigenetic Regulation of Epithelial-Mesenchymal Transition by Hypoxia in Cancer: Targets and Therapy
Current Pharmaceutical Design Coxibs and Cardiovascular Side-Effects: From Light to Shadow
Current Pharmaceutical Design Flavonoids as Natural Inhibitors of Jack Bean Urease Enzyme
Letters in Drug Design & Discovery Recent Patents on Proteasome Inhibitors of Natural Origin
Recent Patents on Anti-Cancer Drug Discovery Carbonic Anhydrases An Overview
Current Pharmaceutical Design Biologically Active Dietary Peptides
Mini-Reviews in Medicinal Chemistry Epigenetic Modifications in Acute Lymphoblastic Leukemia: From Cellular Mechanisms to Therapeutics
Current Gene Therapy Host Microbiomes in Tumor Precision Medicine: How far are we?
Current Medicinal Chemistry Review of Procedures Used for the Extraction of Anti-Cancer Compounds from Tropical Plants
Anti-Cancer Agents in Medicinal Chemistry Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94
Current Topics in Medicinal Chemistry Inflammaging and Proteases in Abdominal Aortic Aneurysm
Current Vascular Pharmacology Treatment of Disorders Characterized by Reversible Airway Obstruction in Childhood: are Anti-cholinergic Agents the Answer?
Current Pharmaceutical Design Targeting Tumors Using Estrogen Receptor Ligand Conjugates
Current Cancer Drug Targets Lycopene Modulation of Molecular Targets Affected by Smoking Exposure
Current Cancer Drug Targets Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry